These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8540123)

  • 1. Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1.
    Lissoni P; Barni S; Ardizzoia A; Frigerio F; Paolorossi F; Cazzaniga M; Tancini G; Rocco F; Aapro M
    Tumori; 1995; 81(4):261-4. PubMed ID: 8540123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in circulating dendritic cells and IL-12 in relation to the angiogenic factor VEGF during IL-2 immunotherapy of metastatic renal cell cancer.
    Bonfanti A; Lissoni P; Bucovec R; Rovelli F; Brivio F; Fumagalli L
    Int J Biol Markers; 2000; 15(2):161-4. PubMed ID: 10883890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
    Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
    Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2.
    Di Felice G; Fumagalli L; Majorca F; Barni S; Ardizzoia A; Tancini G; Lissoni P
    J Biol Regul Homeost Agents; 1996; 10(4):98-9. PubMed ID: 9604779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
    Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
    Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lymphocyte levels before treatment with subcutaneous interleukin-2 and during maintenance treatment in relation to the clinical efficacy in metastatic renal carcinoma].
    Viganò MG; Lissoni P; Barni S; Tancini G; Scardino E; Favini P; Baccalini A; Verweij F; Strada G; Rocco F
    Arch Ital Urol Androl; 1995 Apr; 67(2):143-7. PubMed ID: 7787856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
    J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastatic renal cell carcinoma.
    Lissoni P; Barni S; Ardizzoia A; Andres M; Scardino E; Cardellini P; Della Bitta R; Tancini G
    Tumori; 1993 Dec; 79(6):397-400. PubMed ID: 8171738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor (VEGF) serum levels during cancer immunotherapy with IL-2: preliminary considerations.
    Lissoni P; Fumagalli L; Giani L; Rovelli F; Confalonieri G; Pescia S
    Int J Biol Markers; 1998; 13(2):98-101. PubMed ID: 9803358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood concentrations of interleukin-15 in cancer patients and their variations during interleukin-2 immunotherapy: preliminary considerations.
    Lissoni P; Rovelli F; Mandalà M; Barni S
    Int J Biol Markers; 1998; 13(3):169-71. PubMed ID: 10079393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients.
    Lissoni P; Fumagalli L; Rovelli F; Brivio F; Di Felice G; Majorca F
    Br J Cancer; 1998 Jun; 77(11):1957-60. PubMed ID: 9667674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
    Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani GS
    Anticancer Res; 2007; 27(4C):2985-8. PubMed ID: 17695482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma.
    Lissoni P; Barni S; Ardizzoia A; Crispino S; Paolorossi F; Andres M; Scardino E; Tancini G
    Oncology; 1994; 51(1):59-62. PubMed ID: 8265104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoendocrine therapy with interleukin-2 (IL-2) and medroxyprogesterone acetate (MPA): a randomized study with or without MPA in metastatic renal cancer patients during IL-2 maintenance treatment after response or stable disease to IL-2 subcutaneous therapy.
    Lissoni P; Barni S; Tancini G; Brivio F; Cardellini P; Vaghi M; Fossati V; Frigerio F
    Tumori; 1993 Aug; 79(4):246-9. PubMed ID: 8249176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunotherapy with low-dose subcutaneous interleukin-2 in metastatic renal carcinoma].
    Lissoni P; Barni S; Tancini G; Andres M; Scardino E; Cardellini P; Frascaroli M; Ardizzoia A; Crispino S; Vicini D
    Arch Ital Urol Androl; 1993 Apr; 65(2):123-8. PubMed ID: 8330055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
    Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
    Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy.
    Paolorossi F; Villa S; Barni S; Tancini G; Andres M; Lissoni P
    Tumori; 1995; 81(1):45-7. PubMed ID: 7754541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.